Nevro

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nevro reports strong Q4 earnings, eyes market growth opportunities

Nevro's Q4 2022 performance reflects revenue growth, strong trial rates, and market share gains, with expectations for continued growth.
Challenges include pandemic impact, pricing pressure, and questions on clinical benefits quantification and CEO search progress.
Opportunities lie in market share gains, differentiation through HFX iQ System, and engagement with payers for PDN and NSRBP.
Overall, Nevro anticipates gradual growth throughout 2023, with minimal impact expected from new competitors like Medtronic and Abbott.

Nevro surpasses Q1 expectations, poised for sustained growth ahead

Nevro's Q1 performance exceeded expectations, showcasing strong growth and positive market reception. With a focus on disruptive technologies, new product launches, and market expansion, the company is well-positioned for continued success amidst optimistic market dynamics.

Nevro reports solid Q2 results, focuses on market growth strategies

Nevro's Q2 2023 performance showed revenue growth and focus on market penetration, with challenges in sales force turnover and competition.
Strengths lie in expanded PDN coverage, clinical data emphasis, and reimbursement wins, while opportunities include market growth and enhanced sales productivity.
Addressing challenges through realignment efforts and compensation plans, Nevro aims to leverage market opportunities and drive profitability in the coming months.
Guidance considers turnover impact, territory rebuilding, and sustained business through therapy consultants, positioning Nevro for future growth and success.

Nevro excels in Q3 earnings, eyes growth through innovative therapies

Nevro's Q3 performance reflects strong revenue growth and success in the PDN market, driven by innovative SCS therapy solutions.
The company's strategic focus on commercial execution, market penetration, and operational efficiencies positions them for future success.
Challenges include increasing market penetration, balancing margin expansion with operational efficiency, and careful consideration of acquisitions.
Opportunities lie in leveraging low market penetration, enhancing customer engagement, and collaborating with key experts for continued growth.

Nevro reports solid Q4 revenue growth, eyes market expansion

Nevro's Q4 2023 performance reflects revenue growth driven by PDN sales, with positive EBITDA and strategic acquisitions enhancing market positioning.
While challenges in operational profitability persist, Nevro's focus on market penetration, physician engagement, and salesforce effectiveness present growth opportunities.
Analyst inquiries into market dynamics, competition, and product differentiation underscore the need for Nevro to navigate operational challenges and capitalize on growth prospects.

Nevro surpasses Q1 expectations, eyes market expansion and margin growth

Nevro's Q1 2024 performance exceeded guidance, driven by HFX iQ and increased replacement device candidates, with restructuring efforts to generate savings in 2024.
Strengths include FDA clearance for Nevro1 in SI joint fusion, Android compatibility for HFX iQ, and focus on expanding market penetration.
Challenges include U.S. trials decline, COGS pressure anticipated, and ensuring sales reps are up to speed, while opportunities lie in expanding margins and market penetration.
Overall, Nevro's strategic focus on SI joint fusion products and margin expansion positions them for growth in 2025 and beyond.

Nevro faces revenue decline but pursues strategic growth initiatives

Nevro's Q2 performance reflects revenue challenges but maintains a positive adjusted EBITDA amidst market pressures.
The company's strategic focus on diversification, commercial execution, and exploring strategic options highlights a proactive approach to driving growth.
With a strong cash position and ongoing efforts to navigate challenges and capitalize on opportunities, Nevro is poised for future success.

Nevro reports revenue decline in Q3 but advances AI therapy

Nevro faced revenue decline in Q3 2024 but maintained stability and improved cash position.
Strategic actions to enhance commercial execution and product innovation show promise for future growth.
Challenges in revenue and profitability persist, but opportunities in therapy expansion and market diversification exist.
Continued focus on cost management and strategic exploration to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor...

Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

REDWOOD CITY, Calif., Nov. 24, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President will...

­Nevro to Participate in Citi Bank Head Shoulders Knees and Toes Conference Call Series on November 30th

REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced today that both data abstracts for Painful Diabetic Neuropathy (PDN) and...

Nevro Announces Abstract Presentations for PDN and NSRBP Trials Have Been Accepted for the Late Breaking Trials Plenary Session at NANS 2021 Conference

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 823 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile failures like hedge funds' 2018 losses in Facebook and Apple. Let's take a closer look at what the funds we track think about Nevro Corp (NYSE:NVRO) in this article.

Was The Smart Money Right About Crowding Into Nevro Corp (NVRO)?

Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.

Nevro (NVRO) Rallies 1.3% Despite Delivering Loss in Q3

Nevro Corp. (NVRO) CEO Keith Grossman on Q3 2020 Results - Earnings Call Transcript

Nevro (NVRO) commences plan for manufacturing operations in Costa Rica, thereby expanding its geographic footprint and boosting growth prospects.

Nevro Bolsters Growth Prospects With New Manufacturing Plan

REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- Nevro Corp.

Nevro Initiates Plan for Manufacturing Operations in Costa Rica to Support Future Growth

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

Nevro (NVRO) Down 2.3% Since Last Earnings Report: Can It Rebound?

REDWOOD CITY, Calif., Sept. 1, 2020 /PRNewswire/ -- Nevro Corp.

Nevro to Present at Upcoming Conferences

A Relative Strength Rating upgrade for Nevro shows improving technical performance.

Nevro Earns Relative Strength Rating Upgrade; Hits Key Benchmark

Nevro's (NVRO) domestic and international revenues declined on a year-over-year basis in Q2.

Nevro (NVRO) Q2 Loss Narrower than Expected, Revenues Beat

REDWOOD CITY, Calif., Aug. 7, 2020 /PRNewswire/ -- Nevro Corp.

Nevro to Present at Canaccord Genuity 40th Annual Virtual Growth Conference

Nevro Corp (NVRO) CEO Keith Grossman on Q2 2020 Results - Earnings Call Transcript

Nevro (NVRO) delivered earnings and revenue surprises of 26.67% and 36.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Nevro (NVRO) Reports Q2 Loss, Tops Revenue Estimates

Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

REDWOOD CITY, Calif., July 20, 2020 /PRNewswire/ -- Nevro Corp.

­Nevro to Report Second Quarter 2020 Financial Results

Why Is Nevro (NVRO) Up 7.1% Since Last Earnings Report?

REDWOOD CITY, Calif., June 4, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Roderick ("Rod") MacLeod as Chief Financial Officer,...

Nevro Appoints Finance Executive Roderick MacLeod as Chief Financial Officer

Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.

Nevro's (NVRO) Senza Omnia SCS System Gets CE Mark Approval

REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received CE mark approval for the Senza® Omnia™ Spinal Cord...

Nevro Announces CE Mark Approval of Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain

Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.

Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1

Nevro Corp (NVRO) CEO Keith Grossman on Q1 2020 Results - Earnings Call Transcript

Nevro (NVRO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

News for Nevro Stock (NVRO)